

Consensus of Analysts' Estimates > Pre-Q3 2026



The consensus is the median of analyst estimates which are compiled and calculated by Vara Research. It is based on the projections made by analysts covering Solvay. Any opinions, estimates or forecasts regarding Solvay's performance made by these analysts and therefore also the consensus figures are theirs alone and do not represent opinions or forecasts of Solvay or its Management. By making this consensus information of its results available on a quarterly basis, Solvay does not mean or otherwise imply to endorse such information.

Poll date	Participants	Median TP
12/10/26	17	26.00
BUY	HOLD	SELL
6%	47%	47%

All figures are "Underlying" and "from continuing operations" (1)

KPI expressed in € million except stated DPS (€) and ROCE (%)

	Actuals				Estimates				
	FY 2024 A	FY 2025 A	Q1 2026 A	Q2 2026 A	Q3 2026 E	Q4 2026 E	FY 2026 E	FY 2027 E	FY 2028 E
Net sales	4,686	4,262	997	1,031	1,035	1,008	4,081	4,165	4,291
Basic Chemicals, Sales	2,842	2,630	610	622	634	630	2,499	2,554	2,645
Performance Chemicals, Sales	1,834	1,632	387	409	400	374	1,572	1,618	1,652
Corporate, Sales	10	0	0	0	0	0	0	0	0
EBITDA	1,052	881	219	187	186	183	775	816	853
Basic Chemicals, EBITDA	786	614	129	134	137	140	540	561	587
Performance Chemicals, EBITDA	324	307	84	78	75	68	304	307	318
Corporate, EBITDA	-58	-40	6	-25	-25	-25	-69	-60	-46
EBIT	732	561	145	111	107	107	468	491	534
Net Profit from continuing operations	445	306	78	64	57	53	251	276	312
Gross DPS (€)	2.43	2.43			-	-	2.43	2.43	2.43
Capex	-355	-292	-69	-72	-	-	-280	-300	-301
Free cash flow to Solvay shareholders from continuing operations	361	350	26	-11	-	-	201	262	296
Net Financial Debt	1,544	1,597	1,674	1,829	-	-	1,705	1,719	1,699
ROCE	17.6%	13.6%	13.2%	12.4%	-	-	11.5%	12.5%	13.0%

(1) For full disclosure and definition of Underlying alternative metrics on a proforma basis, please refer to the glossary attached in the Financial reports.